Descriptor English: | Nicardipine | ||||||
Descriptor Spanish: |
Nicardipino
| ||||||
Descriptor Portuguese: | Nicardipino | ||||||
Descriptor French: | Nicardipine | ||||||
Entry term(s): |
Antagonil Cardene Cardene I.V. Cardene SR Dagan Flusemide Hydrochloride, Nicardipine LA, Nicardipine Lecibral Lincil Loxen Lucenfal Nicardipine Hydrochloride Nicardipine LA Nicardipino Ratiopharm Nicardipino Seid Perdipine Ridene Vasonase Y 93 Y-93 Y93 |
||||||
Tree number(s): |
D03.383.725.203.510 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D009529 | ||||||
Scope note: | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Antihypertensive Agents Calcium Channel Blockers Vasodilator Agents |
||||||
Registry Number: | CZ5312222S | ||||||
CAS Type 1 Name: | 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester | ||||||
Previous Indexing: |
Nifedipine/analogs & derivatives (1975-1986) Pyridines (1966-1974) |
||||||
Public MeSH Note: | 87 |
||||||
History Note: | 87 |
||||||
DeCS ID: | 23509 | ||||||
Unique ID: | D009529 | ||||||
NLM Classification: | QV 151 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1987/01/01 | ||||||
Date of Entry: | 1986/06/02 | ||||||
Revision Date: | 2017/05/24 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Nicardipine
- Preferred
Cardene
- Narrower
Cardene SR
- Narrower
Dagan
- Narrower
Flusemide
- Narrower
Lecibral
- Narrower
Lincil
- Narrower
Loxen
- Narrower
Lucenfal
- Narrower
Nicardipine Hydrochloride
- Narrower
Nicardipine LA
- Narrower
Nicardipino Ratiopharm
- Narrower
Perdipine
- Narrower
Ridene
- Narrower
Y-93
- Narrower
Cardene I.V.
- Narrower
Nicardipino Seid
- Narrower
Concept UI |
M0014820 |
Scope note | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. |
Preferred term | Nicardipine |
Concept UI |
M0463035 |
Preferred term | Cardene |
Entry term(s) |
Antagonil Vasonase |
Concept UI |
M0463036 |
Preferred term | Cardene SR |
Concept UI |
M0463044 |
Preferred term | Dagan |
Concept UI |
M0463045 |
Preferred term | Flusemide |
Concept UI |
M0463046 |
Preferred term | Lecibral |
Concept UI |
M0463047 |
Preferred term | Lincil |
Concept UI |
M0463042 |
Preferred term | Loxen |
Concept UI |
M0463043 |
Preferred term | Lucenfal |
Concept UI |
M0463037 |
Preferred term | Nicardipine Hydrochloride |
Entry term(s) |
Hydrochloride, Nicardipine |
Concept UI |
M0014821 |
Preferred term | Nicardipine LA |
Entry term(s) |
LA, Nicardipine |
Concept UI |
M0463050 |
Preferred term | Nicardipino Ratiopharm |
Concept UI |
M0014822 |
Preferred term | Perdipine |
Concept UI |
M0463051 |
Preferred term | Ridene |
Concept UI |
M0373558 |
Preferred term | Y-93 |
Entry term(s) |
Y 93 Y93 |
Concept UI |
M0463038 |
Preferred term | Cardene I.V. |
Concept UI |
M0463034 |
Preferred term | Nicardipino Seid |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey